|
Hal V. Barron (born 1962) is an American clinician-scientist and drug developer currently serving as president of research and development at Calico.〔https://plus.google.com/108880830087528406119/posts/2MdyrE2DX3z〕 He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche.〔http://www.roche.com/media/media_releases/med-cor-2009-04-14.htm〕 __FORCETOC__ ==Career== Barron joined Genentech in 1996 as a clinical scientist and was promoted in 2002 to Vice President of Medical Affairs.〔http://www.gene.com/media/press-releases/5067/2002-05-14/genentech-appoints-hal-barron-vice-presi〕 In 2002 Barron was promoted to vice president of medical affairs and in 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president. On September 18, 2013, Barron was named President of Research and Development of Calico, a new company focusing on health and well-being. The company was created and funded by Google.〔http://googlepress.blogspot.com/2013/09/calico-announcement.html〕 Barron's current academic positions at the University of California, San Francisco include Associate Adjunct Professor of Epidemiology and Biostatistics, and Associate Clinical Professor of Medicine/Cardiology. He has been issued several patents for his work in thrombosis and angiogenesis, and has published more than 90 papers in peer-reviewed scientific journals. He was a member of the board of directors at Alexza Pharmaceuticals. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Hal V. Barron」の詳細全文を読む スポンサード リンク
|